In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was $1.32 for the day, up 0.76% from the previous closing price of $1.31. In other words, the price has increased by $0.76 from its previous closing price. On the day, 1.23 million shares were traded. LXRX stock price reached its highest trading level at $1.3605 during the session, while it also had its lowest trading level at $1.305.
Ratios:
Our analysis of LXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.63 and its Current Ratio is at 5.64. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.53.
Upgrades & Downgrades
In the most recent recommendation for the company, Leerink Partners on March 05, 2025, Downgraded its rating to Market Perform and sets its target price to $1 from $2 previously.
On June 17, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.Leerink Partners initiated its Outperform rating on April 30, 2024, with a $5 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 479686496 and an Enterprise Value of 428686272. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.77 while its Price-to-Book (P/B) ratio in mrq is 3.99. Its current Enterprise Value per Revenue stands at 6.049 whereas that against EBITDA is -7.947.
Stock Price History:
The Beta on a monthly basis for LXRX is 0.71, which has changed by 0.597561 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, LXRX has reached a high of $1.66, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is -7.04%, while the 200-Day Moving Average is calculated to be 36.33%.
Shares Statistics:
LXRX traded an average of 2.30M shares per day over the past three months and 1336290 shares per day over the past ten days. A total of 363.40M shares are outstanding, with a floating share count of 184.00M. Insiders hold about 49.37% of the company’s shares, while institutions hold 23.63% stake in the company. Shares short for LXRX as of 1764288000 were 24226907 with a Short Ratio of 10.52, compared to 1761868800 on 27704594. Therefore, it implies a Short% of Shares Outstanding of 24226907 and a Short% of Float of 18.620001.
Earnings Estimates
. The current rating of Lexicon Pharmaceuticals Inc (LXRX) reflects the combined expertise of 5.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.05 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.16 and -$0.18 for the fiscal current year, implying an average EPS of -$0.17. EPS for the following year is -$0.26, with 5.0 analysts recommending between -$0.19 and -$0.32.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for LXRX’s current fiscal year. The highest revenue estimate was $51.1M, while the lowest revenue estimate was $44.31M, resulting in an average revenue estimate of $47.46M. In the same quarter a year ago, actual revenue was $31.08M
